Drug updated on 12/11/2024
| Dosage Form | Injection (intravenous; 667 mg) |
| Drug Class | Cephalosporin antibacterials |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated for the treatment of Adult patients with Staphylococcus aureus bloodstream infections (bacteremia) (SAB), including those with right-sided infective endocarditis
- Indicated for the treatment of adult patients with acute bacterial skin and skin structure infections (ABSSSI)
- Indicated for the treatment of adult and pediatric patients (3 months to less than 18 years old) with community-acquired bacterial pneumonia (CABP).
Latest News
Summary
- This summary is based on the review of four systematic review(s)/meta-analysis(es). [1-4]
- Ceftobiprole demonstrated comparable clinical success rates to other antibiotics for treating acute bacterial skin and skin structure infections (ABSSSIs) in both intention-to-treat and clinical evaluable populations, with no significant difference in overall clinical response compared to vancomycin-based treatments. However, ceftobiprole was less effective in treating major cutaneous abscesses.
- In burn patients, there is insufficient evidence to assess the effectiveness of ceftobiprole, and for children with hospital-acquired pneumonia, very low certainty of evidence precludes any meaningful conclusions on its effectiveness.
- There is insufficient data on the safety profile of ceftobiprole in burn patients and neonates/children with hospital-acquired pneumonia, with no comprehensive safety outcomes reported. Ceftobiprole had a comparable safety profile to vancomycin-based treatments for ABSSSIs, though it was associated with a higher risk of nausea.
- There is no population types or subgroups information available in the reviewed studies.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Zevtera (ceftobiprole medocaril sodium) Prescribing Information. | 2024 | Basilea Pharmaceutica International Ltd, Allschwil, Switzerland |